Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$40.71 USD

40.71
592,039

-0.53 (-1.29%)

Updated Apr 24, 2024 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

Why the Market Dipped But GSK (GSK) Gained Today

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $39.75, marking a +1.22% move from the previous day.

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

by Zacks Equity Research

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.

Why GSK (GSK) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

by Zacks Equity Research

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

Adaptimmune (ADAP) Down on End of Collaboration With Roche

by Zacks Equity Research

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

GSK (GSK) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

GSK (GSK) closed at $40.80 in the latest trading session, marking a +0.27% move from the prior day.

Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?

by Zacks Equity Research

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal

by Zacks Equity Research

Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

GSK (GSK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

GSK (GSK) concluded the recent trading session at $41.19, signifying a +0.81% move from its prior day's close.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

Here's Why GSK (GSK) Gained But Lagged the Market Today

by Zacks Equity Research

GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.

Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Stock Moves -0.09%: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

by Zacks Equity Research

Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

by Zacks Equity Research

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.